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Abstract 
A global survey of cancer has shown that lung cancer is the most common cause of the new cancer cases and cancer 
deaths in men worldwide. The mortality from lung cancer is more than the combined mortality from breast, pros-
tate and colorectal cancers. The two major histological types of lung cancer are non-small cell lung cancer (NSCLC) 
accounting for about 85 % of cases and small cell lung cancer accounting for 15 % of cases. NSCLC, the more preva-
lent form of lung cancer, is often diagnosed at an advanced stage and has a very poor prognosis. Many factors have 
been shown to contribute to the development of lung cancer in humans including tobacco smoking, exposure to 
environmental carcinogens (asbestos, or radon) and genetic factors. Despite the advances in treatment, lung cancer 
remains one of the leading causes of cancer death worldwide. Interestingly, the overall 5 year survival from lung can-
cer has not changed appreciably in the past 25 years. For this reason, novel and more effective treatments and strate-
gies for NSCLC are critically needed. p90 ribosomal S6 kinase (RSK), a serine threonine kinase that lies downstream of 
the Ras–MAPK (mitogen activated protein kinase) cascade, has been demonstrated to be involved in the regulation 
of cell proliferation in various malignancies through indirect (e.g., modulation of transcription factors) or direct effects 
on the cell-cycle machinery. Increased expression of RSK has been demonstrated in various cancers, including lung 
cancer. This review focuses on the role of RSK in lung cancer and its potential therapeutic application.
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Background
Lung cancer has emerged as a major public health prob-
lem and is the leading cause of cancer related death in 
both men and women worldwide [1, 2]. The expected 
number of lung cancer deaths in the U.S in 2015 is 
158,040 [1]. Unfortunately, standard treatment modali-
ties such as chemotherapy, radiotherapy, and surgery 
have reached a plateau [3]. Therefore, research efforts to 
identify alternatives to the conventional treatment are 
needed. A better understanding of the molecular ori-
gin and pathophysiology of lung cancer are essential to 
developing novel molecular targets for the treatment and 
prevention of lung cancer.
Two major forms of lung carcinoma exist including 
non-small cell lung cancer (NSCLC), which consists 
of approximately 85 % of all lung cancers and small cell 
lung cancer (SCLC), which accounts for 15 % of all lung 
cancers. The 5 year survival rate of NSCLC is about 18 % 
[4] and for small cell lung cancer is 6  % [5]. The three 
major histologic subtypes of NSCLC include adenocar-
cinomas, squamous cell carcinoma and large cell lung 
cancer. Adenocarcinomas, the most common histologi-
cal variant seen in non-smokers and the one which pre-
sents with the best prognosis, accounts for 40  % of all 
lung cancers [6]. It is also the most common variant seen 
in females and adults less than 60  years of age [7]. This 
review focuses on the molecular mechanism and poten-
tial therapeutic targets for lung cancer, with emphasis on 
lung adenocarcinomas.
Review
Molecular origin of lung cancer
The origin of lung cancer is a multistep process induced 
by genetic and epigenetic alterations. These genetic and 
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adaptations to tolerate the oncogenic changes [8]. The 
cellular adaptations attributed to lung cancer include 
self-sufficient growth signals due to the occurrence of 
mutations in proto-oncogenes, lack of sensitivity to anti-
proliferating signals as a result of mutations in tumor 
suppressor genes, evasion of apoptosis, unlimited replica-
tive potential, detachment of tumor cells from the extra-
cellular matrix, which leads to invasion of surrounding 
tissue and basal lamina. Tumor cells also have the capac-
ity of sustained angiogenesis and they transport through 
the blood stream and migrate to distant sites, leading to 
the formation of a metastatic lesion [8, 9]. Cancerous 
cells have also been demonstrated to have a reversed pH 
gradient compared with normal adult cells. They exhibit 
a constitutively higher intracellular pH (pHi) and a lower 
extracellular pH (pHe) [10]. This increased pHi favors cell 
proliferation, cell survival, evasion from apoptosis, cell 
migration and promotes tumor invasion [10]. An under-
standing of the mutated oncogenes, genetic alterations 
and the cellular adaptations has paved the road for iden-
tifying molecular therapeutic targets.
Epidermal growth factor and the epidermal growth factor 
receptor in lung adenocarcinomas
Epidermal growth factor receptor (EGFR) is overex-
pressed in 32–81 % of NSCLC [11]. EGFR plays a major 
role in activating several downstream signaling pathways 
like Ras/Raf/MEK/MAPK and the pathway consisting of 
phosphoinositide 3-kinase (PI3K), Akt, and the mam-
malian target of rapamycin (mTOR). Activation of these 
major downstream signaling pathways contribute to the 
cell proliferation, increased survival, invasiveness, meta-
static spread, and angiogenesis in tumor cells [2]. Numer-
ous therapeutics agents are available to target EGFR in 
NSCLC including Erlotinib, Geftinib and Cetuximab. 
Despite the importance of EGFR in mediating NSCLC, 
many of the available therapeutic agents targeting EGFR 
are ineffective [11]. Acquired resistance to the anti-EGFR 
agents also results from secondary mutations specifically 
in the exon 20 of the EGFR gene [3, 8]. Recent studies 
have also suggested that Ras mutations in lung adeno-
carcinomas were found to be associated with resistance 
to EGFR tyrosine kinase inhibitors (TKI) [3]. In addi-
tion, persistent activity of the mitogen activated protein 
kinase/extracellular-signal-regulated kinase (MAPK/
ERK) pathway and the PI3K/Akt kinase pathway could 
contribute to the resistance of NSCLC to EGFR inhibi-
tors [12]. Other proposed resistance mechanisms to 
EGFR inhibitors include amplification of the MET proto-
oncogene, which activates PI3K pathway independent 
of the EGFR [13] and activation of other tyrosine kinase 
receptors such as the insulin like growth factor recep-
tor 1 [2]. This has directed research activity towards 
identifying other molecular targets like Ras, Raf, MAPK 
and ERK, which may be beneficial in the management of 
lung adenocarcinomas.
Ras proto‑oncogene
The Ras proto-oncogene plays an important role in the 
transduction of growth promoting signals from the cell 
membrane to the nucleus and the resulting cell prolif-
eration [9]. The Ras proto-oncogene family (KRas, HRas, 
NRas and RRas) encodes four highly homologous 21 kDa 
membrane-bound proteins. Proteins encoded by the Ras 
genes exist in two states: an active state, in which GTP is 
bound to the Ras and an inactive state, where the GTP 
has been cleaved to GDP through the intrinsic GTPase 
activity [3]. The GTPase Ras activates Raf (A-, B- and 
C-Raf isoforms) [14]. The signal for cell proliferation is 
ultimately transmitted by a cascade of RAS-dependent 
kinases, which activates the MAPKs. It is noteworthy 
that 15–30  % of lung adenocarcinomas harbor activat-
ing mutations in the Ras family members, especially the 
KRas [3]. Mutations in the Ras induces defects in the 
intrinsic GTPase activity of Ras resulting in continuous 
cell proliferation [9]. The importance of KRas in lung car-
cinomas makes it a promising therapeutic target [8, 15]. 
However, Ras inhibitors (farnesyl transferase inhibitors) 
which inhibit post-translational modification and mem-
brane localization of Ras proteins have been unsuccess-
ful in clinical trials. This could be attributed to the fact 
that these inhibitors are not selectively active in tumors 
with KRas or NRas mutations [8, 15]. Recent research has 
focused on investigating downstream effectors of RAS 
including MAPKs, since they control fewer of the down-
stream pathways [8, 16].
Mitogen activated protein kinases and lung 
adenocarcinomas
The MAPK/ERK pathway is activated by various extracel-
lular stimuli including mitogens, cytokines, growth fac-
tors and cellular stresses [17]. The binding of EGF to the 
EGFR activates the Ras proto-oncogene, which then acti-
vates the Raf kinase. In turn, Raf phosphorylates and acti-
vates the MAPK/ERK kinase (MEK)1/2, a dual-specificity 
protein kinase, which activate ERK1/2. Once activated, 
the ERK1/2 phosphorylates several substrates including 
members of the RSK (90 kDa ribosomal S6 kinase) family 
[14]. The Ras–MAPK also activates the PI3K/AKT path-
way that regulates the normal cell proliferation, survival, 
growth and differentiation [8].
Mutations or overexpression of many of the signaling 
components in the MAPK pathway can confer onco-
genic potential and lead to several human cancers [17, 
18]. Activation of the Ras/Raf/MEK/MAPK via activat-
ing mutations in KRas occurs in approximately 30  % of 
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adenocarcinomas [3]. Activation of downstream signal-
ing pathways such as PI3K and MAPK occur independent 
of the EGFR signaling, therefore, rendering KRas mutant 
tumors resistant to anti EGFR agents and chemotherapy 
[19]. Therefore, targeting the downstream effectors of 
this pathway represent an untapped pool of possible ther-
apeutic targets in the treatment of lung cancer. Currently, 
two MEK1/2 inhibitors, selumetinib and trametinib, have 
been tested in many different cancer types including 
NSCLC [17]. Selumetinib, which is the agent furthest in 
development raised a concerning rate of hospitalization, 
grade 3 or 4 neutropenia, and febrile neutropenia [17]. 
Therefore, research efforts have been directed to identi-
fying a small set of effectors such as RSK, which are less 
likely to cause severe adverse effects [16, 20].
RSK family of kinases
The efforts to identify the kinase activity responsible for 
the phosphorylation of ribosomal protein S6 (rpS6), led 
to the purification of an intracellular kinase that phos-
phorylated 40S ribosomal subunit from unfertilized 
Xenopus laevis eggs by Erikson and Maller laboratories 
in 1985. This kinase was initially referred to as ribosomal 
S6 kinase (S6K) [21]. The identification of two protein 
kinases of 85–90  kDa (S6KI and S6KII) by biochemical 
purification, led to the cloning of cDNAs encoding highly 
homologous proteins that were later renamed p90 riboso-
mal S6 kinase [14]. The RSK family of proteins comprises 
a group of highly conserved serine/threonine kinases that 
lie downstream of the Ras–MAPK pathway and regulate 
diverse cellular processes such as cell growth and motil-
ity, cell proliferation and cell survival [14, 18].
Structure of RSK
The structure of RSK is characterized by two distinct 
kinase domains separated by a linker region of about 100 
amino acids and flanked by N- and C-terminal ends [18]. 
The RSKs are 73–80 % identical with each other and are 
mostly divergent in their N- and C-terminal sequences 
[14, 22]. The carboxyl-terminal kinase domain (CTKD) 
is closely related to the calcium/calmodulin-dependent 
protein kinase (CAMK) family. In contrast, the amino-
terminal kinase domain (NTKD) is homologous to that 
of AGC kinases. The CTKD is responsible for auto-
phosphorylation of RSK and the NTKD is involved in 
substrate phosphorylation [18]. Finally, the C-terminal 
region contains an ERK1/2 docking site also known as 
the D-domain, which is responsible for the docking and 
activation of RSK by ERK1/2 [22].
RSK family
In humans, the RSK family comprises of four isoforms 
(RSK1 to −4) and two structurally related cousins, called 
RSK-like protein kinase/mitogen and stress activated 
kinase-1 (RLPK/MSK1) and RSK-B (MSK2) [22]. Analy-
sis of the expression patterns of RSK isoforms showed 
that RSK1 mRNA are more abundant in the lung, kid-
ney, pancreas, bone marrow and T cells. RSK2 mRNA 
are predominantly found in T cells, lymph nodes, and the 
prostate. RSK3 transcripts are mainly expressed in the 
lung, brain, spinal cord, and retina. Interestingly, RSK4 
mRNA expression in both adult and embryonic tissues 
is much lower than that of the other three isoforms. But 
Northern blotting of lysates from adult mouse tissues has 
revealed the expression of RSK4 mRNA in the brain, cer-
ebellum, heart, renal tissue and skeletal muscle [18, 22].
Activators of RSK
RSKs are directly phosphorylated and activated by 
ERK1/2 and phosphoinositide dependent protein kinase 
1 (PDK1) in response to various stimuli including growth 
factors, neurotransmitters and phorbol esters [18]. The 
MSKs are potently activated by both the ERK1/2 and 
the p38 pathways and are generally thought to be more 
responsive to cellular stress [18, 23]. Unlike the RSKs, 
MSK is usually located in the nucleus of cells and phos-
phorylates transcription factors [24]. Mutational analysis 
revealed that four phosphorylation sites (Ser221, Ser363, 
Ser380, and Thr573 in human RSK1) are essential for 
RSK activation upon mitogenic stimulation [10, 19]. The 
phosphorylation of Thr573 in the CTKD occurs follow-
ing ERK activation. This activation also requires ERK 
docking at the D domain. The Ser380 is auto-phospho-
rylated by the activated CTKD [18]. Phosphorylation of 
Ser221 in the NTKD is mediated by PDK1 for RSK1–3, 
which leads to complete activation of RSK. This is further 
emphasized in PDK1 deficient cells, where mitogens do 
not stimulate RSK1–3 activity [14]. Once activated the 
RSKs may remain associated with the membrane, or in 
the cytosol or translocate to the nucleus, and eventually 
can phosphorylate substrates throughout the cell [18].
Biological function of RSK isoforms
The biological function of the RSK isoforms is to regulate 
cell-cycle progression and cell proliferation, cell growth 
and protein synthesis, nuclear signaling, cell migration 
and cell survival [14, 23].
Activation of cytosolic and nuclear proteins 
through phosphorylated RSK
Activation of the RSK protein kinase results in the phos-
phorylation of functionally diverse RSK substrates in 
the cytosol and nucleus. In the cytosol, phosphoryl-
ated RSK substrates include glycogen synthase kinase 3 
(GSK3), protein phosphatase 1, LK B1, L1 CAM (a neu-
ral cell adhesion molecule), the Ras exchange factor; and 
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membrane-associated tyrosine and threonine specific 
cyclin dependent kinase 1 or cell division cycle protein 
[17]. Nuclear translocation of phosphorylated RSK fol-
lowing mitogenic stimulation leads to phosphorylation of 
a variety of transcription factors including CREB, CREB 
binding protein (CBP), serum response factor (SRF), 
p300, ER81, oestrogen receptor-α (ERα), c-Fos, nuclear 
factor-Κb (NF-κB), NFATc4, NFAT3 and the transcrip-
tion initiation factor TIF1A [23, 24]. Activation of these 
cytosolic and nuclear proteins contributes to the initia-
tion and progression of tumorgenesis [23].
RSK and cell cycle machinery
RSKs are involved in the regulation of cell-cycle progres-
sion through phosphorylation of several mediators of the 
cell-cycle machinery. RSK mediated phosphorylation 
inactivates membrane-associated tyrosine and threo-
nine specific CDC2 inhibitory kinase-1 (Myt1), leading 
to G2–M cell-cycle progression [18]. RSK1 and RSK2 
have also been shown to promote G1-phase progres-
sion by phosphorylating the cyclin-dependent kinase 
(CDK) inhibitor p27KIP1. In addition, RSK phosphoryl-
ates serum response factor (SRF) and contributes to the 
transcriptional activation of c-FOS. Activation of c-FOS 
results in the activation of cyclin D1, promoting G1–S 
phase progression [18]. RSK phosphorylates and inhibits 
glycogen synthase kinase (GSK3), which has been sug-
gested to promote stabilization of cyclin D1 and MYC, 
resulting in cell cycle progression and cell survival [18, 
23]. In addition, RSK phosphorylates eEF2K and the 
translation-initiation factor eIF4B, which in turn stimu-
lates its recruitment to the translation-initiation com-
plex and contributes to cell growth and survival [14]. The 
phosphorylation of transcription factors such as CREB by 
RSK1 and RSK2 promotes cell survival by activating pro-
survival genes such as members of the B cell lymphoma 
protein-2 (Bcl2) family [22]. Clearly, activation of RSK is 
critical in the phosphorylation of numerous mediators 
involved in the cell-cycle machinery.
RSK and apoptosis
High levels of endogenous Bcl2 are expressed in several 
lung cancer cell lines including those from NSCLC and 
SCLC [9]. The fate of these cancer cells is largely depend-
ent on the balance between inhibitory and stimulatory 
apoptosis signals from the Bcl2 family. The subfam-
ily members including Bcl2, Bcl-XL, and Mcl-1 inhibit 
apoptosis, whereas the Bax subfamily, consisting of Bax 
and Bak, as well as the BH3-only subfamily, including 
Bad, Bid, Bok, Bik, and Bim, promotes apoptosis [25].
RSK enhances cell survival via anti-apoptotic mecha-
nisms [16, 22]. RSK phosphorylates the pro-apoptotic 
protein Bad and enhances its binding to 14-3-3 proteins. 
This prevents Bad from antagonizing the pro-survival 
function of Bcl-XL [22]. The RSK mediated phospho-
rylation of the death associated protein kinase (DAPK) 
leads to inhibition of its pro-apoptotic function [26]. 
RSK1/2 mediated phosphorylation of a tumor suppres-
sor gene Bim-EL prevents its pro-apoptotic function 
[22, 27]. RSK1 directly inhibits caspase activity leading 
to increased cell survival [28]. Taken together, these data 
indicate that RSKs are invariably involved in cell prolif-
eration and survival, making them promising therapeutic 
targets for the treatment of cancer.
RSK and lung cancer
RSKs have been demonstrated to be over expressed or 
hyper activated in several cancers including breast can-
cer, lung cancer, prostate cancer, head and neck squa-
mous cell carcinoma, ovarian carcinoma, multiple 
myeloma, melanoma and osteosarcoma [16, 29]. Differ-
ent RSK isoforms behave differently depending on the 
type of cancer.
Activation or overexpression of RSK in lung cancer cells 
inhibits cell death via inactivation of the pro-apoptotic 
protein Bad [16]. Similarly, Bim-EL, which is sequentially 
phosphorylated by ERK and RSK1 or RSK2, is decreased 
in NSCLC cells with EGFR-activating mutations. The 
decrease in Bim-EL results in proteosomal degradation 
of BIM-EL and increased cell survival [30]. When the 
H-Ras/ERK pathway is activated in tumor cells, BIM-EL 
is eliminated by proteasomal degradation [27]. Addition-
ally the expression of DAPKm which behaves as a tumor 
suppressor, is commonly silenced in lung cancer through 
DNA methylation [14]. Lara and colleagues observed 
that RSK4 is overexpressed in more than 50 % of primary 
malignant lung cancers though its levels are undetect-
able in normal cells [22]. Interesting, a previous report by 
Lara et al. demonstrated that the knock down of p90RSK 
isoform 1 enhanced the metastatic potential of A549 
lung adenocarcinoma cells. Similarly, an siRNA kinome 
library screen in A549 cells demonstrated that p90RSK 
isoform 1 silencing increased migration and invasion 
[30]. Moreover, Lara et al. [29] reported that there is an 
increased migration in A549 cells caused by RSK 2 and 
4. Clearly, the exact role and signaling pathway of the 
respective RSK isoforms in lung cancer remain unknown.
RSK inhibitors
The identification of RSK inhibitors has uncovered an 
unexpected link between RSK activity and cell prolif-
eration. Several pan-RSK small-molecule inhibitors 
exist including two competitive inhibitors that target 
the NTKD (SL-0101 and BI-D1870) and an irreversi-
ble inhibitor of the CTKD, FMK [22]. The first specific 
inhibitor identified for p90 RSK was SL0101, which was 
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isolated from the tropical plant Forsteronia refracta. 
When tested against a panel of 70 kinases, it was shown 
to target RSK1 and RSK2 in the nanomolar range (IC50 
for RSK2, 90  nmol/L at 10  mmol/L ATP) while having 
no significant activity against other tested AGC kinases 
[28]. The dihydropteridinone BI-D1870 is a revers-
ible inhibitor that competes with ATP by binding to the 
NTKD ATP-interacting sequence. BI-D1870 is remark-
ably selective for RSK relative to other AGC kinases 
[31] and its in vitro IC50 was shown to be approximately 
15–30  nM at an ATP concentration of 100  μM [32]. In 
vivo results indicate that to completely inhibit the phos-
phorylation of RSK substrates in  vitro, a concentration 
of 10 μM BI-D1870 is required [32]. The pyrrolopyrimi-
dine FMK (fluoromethylketone) is an irreversible inhibi-
tor that covalently modifies the CTKD of RSK1, RSK2 
and RSK4. FMK is a potent and specific inhibitor of RSK 
and was shown to inhibit RSK2 at an IC50 of 15 nM and 
an EC50 of 200 nM in vitro [33]. Recently another CTKD 
inhibitor, dibenzyl trisulfide, has been isolated from the 
Petiveria alliacea L plant. It specifically inhibits the RSK1 
isoform at a concentration of 10 µM [20]. Therefore, the 
discovery of RSK-specific inhibitors will definitely help to 
advance the knowledge of RSK-mediated mechanisms in 
lung cancer and to test the potential of these inhibitors 
in pre-clinical studies. Our own unpublished data sug-
gests that exposure of A549 lung adenocarcinoma cells to 
BI-D1870 decreases RSK1 protein expression and is asso-
ciated with a decrease in cell migration and proliferation. 
Indeed, with the discovery of RSK-specific inhibitors fur-
ther studies will need to be carried to verify the efficacy 
of RSK inhibitors as single agents or in combination with 
other anti-cancer agents in the lung cancer setting.
Conclusion
RSKs are an important downstream effector of the Ras–
Raf–MAPK signaling pathway. They play a crucial role in 
the regulation of cellular proliferation, growth, and sur-
vival in a variety of tumors. Based on our recent advances 
in the understanding of the different isoforms of RSK 
and the mechanisms by which they affect tumorgenesis, 
invasion and metastasis these agents might prove to be 
promising targets in the chemotherapy of lung adenocar-
cinomas particularly those harboring oncogenic muta-
tions in components of the Ras signaling pathway.
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